Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin

Bradley H Pollock, Sarah Elmore, Amelia Romoser, Lili Tang, Min su Kang, Kathy Xue, Marisa Rodriguez, Nicole A. Dierschke, Holly G. Hayes, H. Andrew Hansen, Fernando Guerra, Jia Sheng Wang, Timothy Phillips

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

South Texas currently has the highest incidence of hepatocellular carcinoma (HCC) in the United States, a disease that disproportionately affects Latino populations in the region. Aflatoxin B1 (AFB1) is a potent liver carcinogen that has been shown to be present in a variety of foods in the United States, including corn and corn products. Importantly, it is a dietary risk factor contributing to a higher incidence of HCC in populations frequently consuming AFB1-contaminated diets. In a randomised double-blind placebo controlled trial, we evaluated the effects of a 3-month administration of ACCS100 (refined calcium montmorillonite clay) on serum AFB1–lysine adduct (AFB-Lys) level and serum biochemistry in 234 healthy men and women residing in Bexar and Medina counties, Texas. Participants recruited from 2012 to 2014 received either a placebo, 1.5 g or 3 g ACCS100 each day for 3 months, and no treatment during the fourth month. Adverse event rates were similar across treatment groups and no significant differences were observed for serum biochemistry and haematology parameters. Differences in levels of AFB-Lys at 1, 3 and 4 months were compared between placebo and active treatment groups. Although serum AFB-Lys levels were decreased by month 3 for both treatment groups, the low dose was the only treatment that was significant (p = 0.0005). In conclusion, the observed effect in the low-dose treatment group suggests that the use of ACCS100 may be a viable strategy to reduce dietary AFB1 bioavailability during aflatoxin outbreaks and potentially in populations chronically exposed to this carcinogen.

Original languageEnglish (US)
Pages (from-to)1346-1354
Number of pages9
JournalFood Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment
Volume33
Issue number8
DOIs
StatePublished - Aug 2 2016

Fingerprint

Bentonite
Aflatoxin B1
Aflatoxins
montmorillonite
aflatoxin B1
at-risk population
aflatoxins
placebos
Biochemistry
clay
carcinogens
hepatoma
Calcium
calcium
Carcinogens
biochemistry
corn products
Population
incidence
Placebos

Keywords

  • AFB–lysine adduct
  • Aflatoxin
  • biomarkers
  • calcium montmorillonite clay
  • clinical intervention trial
  • enterosorption

ASJC Scopus subject areas

  • Food Science
  • Chemistry(all)
  • Toxicology
  • Public Health, Environmental and Occupational Health
  • Health, Toxicology and Mutagenesis

Cite this

Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin. / Pollock, Bradley H; Elmore, Sarah; Romoser, Amelia; Tang, Lili; Kang, Min su; Xue, Kathy; Rodriguez, Marisa; Dierschke, Nicole A.; Hayes, Holly G.; Hansen, H. Andrew; Guerra, Fernando; Wang, Jia Sheng; Phillips, Timothy.

In: Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, Vol. 33, No. 8, 02.08.2016, p. 1346-1354.

Research output: Contribution to journalArticle

Pollock, BH, Elmore, S, Romoser, A, Tang, L, Kang, MS, Xue, K, Rodriguez, M, Dierschke, NA, Hayes, HG, Hansen, HA, Guerra, F, Wang, JS & Phillips, T 2016, 'Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin', Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, vol. 33, no. 8, pp. 1346-1354. https://doi.org/10.1080/19440049.2016.1198498
Pollock, Bradley H ; Elmore, Sarah ; Romoser, Amelia ; Tang, Lili ; Kang, Min su ; Xue, Kathy ; Rodriguez, Marisa ; Dierschke, Nicole A. ; Hayes, Holly G. ; Hansen, H. Andrew ; Guerra, Fernando ; Wang, Jia Sheng ; Phillips, Timothy. / Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin. In: Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment. 2016 ; Vol. 33, No. 8. pp. 1346-1354.
@article{dab4bdd8a6ed4f1c96c7df5207530e26,
title = "Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin",
abstract = "South Texas currently has the highest incidence of hepatocellular carcinoma (HCC) in the United States, a disease that disproportionately affects Latino populations in the region. Aflatoxin B1 (AFB1) is a potent liver carcinogen that has been shown to be present in a variety of foods in the United States, including corn and corn products. Importantly, it is a dietary risk factor contributing to a higher incidence of HCC in populations frequently consuming AFB1-contaminated diets. In a randomised double-blind placebo controlled trial, we evaluated the effects of a 3-month administration of ACCS100 (refined calcium montmorillonite clay) on serum AFB1–lysine adduct (AFB-Lys) level and serum biochemistry in 234 healthy men and women residing in Bexar and Medina counties, Texas. Participants recruited from 2012 to 2014 received either a placebo, 1.5 g or 3 g ACCS100 each day for 3 months, and no treatment during the fourth month. Adverse event rates were similar across treatment groups and no significant differences were observed for serum biochemistry and haematology parameters. Differences in levels of AFB-Lys at 1, 3 and 4 months were compared between placebo and active treatment groups. Although serum AFB-Lys levels were decreased by month 3 for both treatment groups, the low dose was the only treatment that was significant (p = 0.0005). In conclusion, the observed effect in the low-dose treatment group suggests that the use of ACCS100 may be a viable strategy to reduce dietary AFB1 bioavailability during aflatoxin outbreaks and potentially in populations chronically exposed to this carcinogen.",
keywords = "AFB–lysine adduct, Aflatoxin, biomarkers, calcium montmorillonite clay, clinical intervention trial, enterosorption",
author = "Pollock, {Bradley H} and Sarah Elmore and Amelia Romoser and Lili Tang and Kang, {Min su} and Kathy Xue and Marisa Rodriguez and Dierschke, {Nicole A.} and Hayes, {Holly G.} and Hansen, {H. Andrew} and Fernando Guerra and Wang, {Jia Sheng} and Timothy Phillips",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/19440049.2016.1198498",
language = "English (US)",
volume = "33",
pages = "1346--1354",
journal = "Food Additives and Contaminants",
issn = "0265-203X",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin

AU - Pollock, Bradley H

AU - Elmore, Sarah

AU - Romoser, Amelia

AU - Tang, Lili

AU - Kang, Min su

AU - Xue, Kathy

AU - Rodriguez, Marisa

AU - Dierschke, Nicole A.

AU - Hayes, Holly G.

AU - Hansen, H. Andrew

AU - Guerra, Fernando

AU - Wang, Jia Sheng

AU - Phillips, Timothy

PY - 2016/8/2

Y1 - 2016/8/2

N2 - South Texas currently has the highest incidence of hepatocellular carcinoma (HCC) in the United States, a disease that disproportionately affects Latino populations in the region. Aflatoxin B1 (AFB1) is a potent liver carcinogen that has been shown to be present in a variety of foods in the United States, including corn and corn products. Importantly, it is a dietary risk factor contributing to a higher incidence of HCC in populations frequently consuming AFB1-contaminated diets. In a randomised double-blind placebo controlled trial, we evaluated the effects of a 3-month administration of ACCS100 (refined calcium montmorillonite clay) on serum AFB1–lysine adduct (AFB-Lys) level and serum biochemistry in 234 healthy men and women residing in Bexar and Medina counties, Texas. Participants recruited from 2012 to 2014 received either a placebo, 1.5 g or 3 g ACCS100 each day for 3 months, and no treatment during the fourth month. Adverse event rates were similar across treatment groups and no significant differences were observed for serum biochemistry and haematology parameters. Differences in levels of AFB-Lys at 1, 3 and 4 months were compared between placebo and active treatment groups. Although serum AFB-Lys levels were decreased by month 3 for both treatment groups, the low dose was the only treatment that was significant (p = 0.0005). In conclusion, the observed effect in the low-dose treatment group suggests that the use of ACCS100 may be a viable strategy to reduce dietary AFB1 bioavailability during aflatoxin outbreaks and potentially in populations chronically exposed to this carcinogen.

AB - South Texas currently has the highest incidence of hepatocellular carcinoma (HCC) in the United States, a disease that disproportionately affects Latino populations in the region. Aflatoxin B1 (AFB1) is a potent liver carcinogen that has been shown to be present in a variety of foods in the United States, including corn and corn products. Importantly, it is a dietary risk factor contributing to a higher incidence of HCC in populations frequently consuming AFB1-contaminated diets. In a randomised double-blind placebo controlled trial, we evaluated the effects of a 3-month administration of ACCS100 (refined calcium montmorillonite clay) on serum AFB1–lysine adduct (AFB-Lys) level and serum biochemistry in 234 healthy men and women residing in Bexar and Medina counties, Texas. Participants recruited from 2012 to 2014 received either a placebo, 1.5 g or 3 g ACCS100 each day for 3 months, and no treatment during the fourth month. Adverse event rates were similar across treatment groups and no significant differences were observed for serum biochemistry and haematology parameters. Differences in levels of AFB-Lys at 1, 3 and 4 months were compared between placebo and active treatment groups. Although serum AFB-Lys levels were decreased by month 3 for both treatment groups, the low dose was the only treatment that was significant (p = 0.0005). In conclusion, the observed effect in the low-dose treatment group suggests that the use of ACCS100 may be a viable strategy to reduce dietary AFB1 bioavailability during aflatoxin outbreaks and potentially in populations chronically exposed to this carcinogen.

KW - AFB–lysine adduct

KW - Aflatoxin

KW - biomarkers

KW - calcium montmorillonite clay

KW - clinical intervention trial

KW - enterosorption

UR - http://www.scopus.com/inward/record.url?scp=84980011841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980011841&partnerID=8YFLogxK

U2 - 10.1080/19440049.2016.1198498

DO - 10.1080/19440049.2016.1198498

M3 - Article

C2 - 27321368

AN - SCOPUS:84980011841

VL - 33

SP - 1346

EP - 1354

JO - Food Additives and Contaminants

JF - Food Additives and Contaminants

SN - 0265-203X

IS - 8

ER -